Alexandriah Alas
Obstetrics/Gynecology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Alexandriah Alas’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
State licence records
1 licence
- Texas Q9107Physician License · since 2016 · expires 2025-08-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$72,061
Medicare paid this office $72,061 for 180 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 86 | $9,778 | $91 |
| Botox | 15 | $8,169 | None |
| New patient visit (45+ min) | 66 | $7,189 | $109 |
| Creation of sling around urethra in female to control leakage | 12 | $4,949 | $412 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $4,922 | $290 |
See all 12 services
| Return visit (30+ min) | 86 | $9,778 | $91 |
| Botox | 15 | $8,169 | None |
| New patient visit (45+ min) | 66 | $7,189 | $109 |
| Creation of sling around urethra in female to control leakage | 12 | $4,949 | $412 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $4,922 | $290 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 12 | $3,531 | $294 |
| Short return visit (20+ min) | 31 | $2,008 | $61 |
| Pelvic exam | 35 | $575 | $16 |
| Ultrasound measurement of bladder capacity after voiding | 49 | $450 | $9 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 14 | $203 | $14 |
| Electronic assessment of bladder emptying | 12 | $61 | $5 |
| Urinalysis, manual test | 11 | $38 | $3 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
180 Original Medicare patients in 2024. Average age 74 · Women 100% · Also on Medicaid 11% · Health risk score 1.00. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 73% · Diabetes 31% · Depression 25% · Coronary heart disease 22% · Chronic kidney disease 18% · Atrial fibrillation 15% · Heart failure 11% · Cancer 11% · COPD 8% · Dementia 7% · Stroke 6%.
The office billed $351,968, Medicare allowed $95,794 and paid $72,061; for 2,178 services of 54 kinds; $8,172 of it was for drugs given in the office and $63,888 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 180 | 2,178 | 74 | 1.00 | $351,968 | $72,061 |
| 2023 | 198 | 4,231 | 74 | 1.02 | $444,601 | $107,615 |
| 2022 | 221 | 4,254 | 74 | 0.98 | $515,607 | $129,436 |
| 2021 | 207 | 3,619 | 75 | 1.17 | $439,010 | $115,127 |
| 2020 | 168 | 2,907 | 74 | 1.31 | $370,581 | $89,713 |
| 2019 | 182 | 2,617 | 73 | 1.22 | $352,557 | $90,256 |
| 2018 | 162 | 1,289 | 72 | 1.29 | $334,329 | $86,565 |
| 2017 | 76 | 510 | 71 | 1.36 | $187,907 | $45,636 |
| 2016 | 20 | 55 | 68 | 2.21 | $10,402 | $3,168 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Botox | 18 | $16,521 | None |
| Return visit (30+ min) | 118 | $15,922 | $90 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 39 | $11,244 | $288 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 18 | $9,489 | $297 |
| New patient visit (45+ min) | 80 | $8,651 | $108 |
| Creation of sling around urethra in female to control leakage | 17 | $8,438 | $496 |
| Insertion of device into abdomen with pressure and urine flow rate study | 39 | $5,725 | $147 |
| Repair of herniated rectum into vaginal wall | 14 | $4,094 | $292 |
| Short return visit (20+ min) | 42 | $2,910 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $2,073 | $130 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 29 | $724 | $25 |
| Insertion of temporary bladder tube | 18 | $572 | $32 |
| Ultrasound measurement of bladder capacity after voiding | 62 | $446 | $7 |
| Electronic assessment of bladder emptying | 39 | $200 | $5 |
| Simple timed assessment of bladder emptying | 22 | $152 | $7 |
| Automated urinalysis test | 33 | $77 | $2 |
2022: 20 services
| Return visit (30+ min) | 149 | $21,188 | $91 |
| Botox | 24 | $15,491 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 52 | $15,279 | $294 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 24 | $10,098 | $297 |
| New patient visit (45+ min) | 77 | $8,520 | $111 |
| Creation of sling around urethra in female to control leakage | 18 | $8,384 | $466 |
| Insertion of device into abdomen with pressure and urine flow rate study | 50 | $7,829 | $157 |
| Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 15 | $4,742 | $279 |
| Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies | 15 | $4,030 | $183 |
| Short return visit (20+ min) | 40 | $2,995 | $57 |
| Diagnostic exam of bladder and urethra using an endoscope | 20 | $2,802 | $140 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,427 | $95 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 39 | $978 | $25 |
| 3d radiographic procedure with computerized image postprocessing | 14 | $907 | $57 |
| Limited ultrasound scan of pelvis | 24 | $907 | $36 |
| Insertion of temporary bladder tube | 25 | $702 | $28 |
| Simple timed assessment of bladder emptying | 63 | $619 | $10 |
| Ultrasound measurement of bladder capacity after voiding | 63 | $529 | $8 |
| Electronic assessment of bladder emptying | 51 | $276 | $5 |
| Automated urinalysis test | 28 | $62 | $2 |
2021: 16 services
| Return visit (30+ min) | 125 | $20,425 | $97 |
| Botox | 15 | $13,208 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 38 | $11,652 | $307 |
| New patient visit (45+ min) | 93 | $10,696 | $115 |
| Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies | 18 | $7,041 | $176 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $6,153 | $308 |
| Insertion of device into abdomen with pressure and urine flow rate study | 38 | $5,671 | $149 |
| Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 18 | $5,068 | $282 |
| Insertion of temporary bladder tube | 91 | $3,115 | $34 |
| Short return visit (20+ min) | 38 | $2,891 | $66 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $1,825 | $140 |
| Fitting and insertion of vaginal support device | 16 | $975 | $51 |
| Pessary, reusable, non rubber, any type | 17 | $949 | $47 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 33 | $862 | $26 |
| Electronic assessment of bladder emptying | 39 | $214 | $5 |
| Ultrasound measurement of bladder capacity after voiding | 17 | $152 | $8 |
2020: 17 services
| Botox | 15 | $10,482 | None |
| Return visit (30+ min) | 90 | $9,044 | $75 |
| Surgical repair of vaginal defect using an endoscope | 11 | $8,552 | $777 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 30 | $8,117 | $271 |
| New patient visit (45+ min) | 64 | $7,230 | $113 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $5,045 | $280 |
| Creation of sling around urethra in female to control leakage | 13 | $4,952 | $381 |
| Short return visit (20+ min) | 57 | $4,151 | $51 |
| Insertion of device into abdomen with pressure and urine flow rate study | 28 | $3,529 | $126 |
| Insertion of temporary bladder tube | 68 | $2,204 | $32 |
| Diagnostic exam of bladder and urethra using an endoscope | 12 | $1,641 | $137 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,052 | $58 |
| Fitting and insertion of vaginal support device | 15 | $943 | $47 |
| Pessary, reusable, non rubber, any type | 15 | $929 | $46 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 28 | $738 | $26 |
| Electronic assessment of bladder emptying | 28 | $135 | $5 |
| Automated urinalysis test | 14 | $38 | $2 |
2019: 14 services
| Return visit (30+ min) | 118 | $16,565 | $77 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 33 | $9,032 | $274 |
| Botox | 15 | $8,287 | None |
| New patient visit (45+ min) | 67 | $7,887 | $118 |
| Creation of sling around urethra in female to control leakage | 12 | $5,580 | $429 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 14 | $4,501 | $265 |
| Short return visit (20+ min) | 59 | $4,090 | $51 |
| Insertion of device into abdomen with pressure and urine flow rate study | 33 | $3,489 | $106 |
| Insertion of temporary bladder tube | 87 | $3,326 | $33 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 31 | $824 | $27 |
| Fitting and insertion of vaginal support device | 13 | $785 | $46 |
| Pessary, reusable, non rubber, any type | 12 | $693 | $46 |
| Electronic assessment of bladder emptying | 33 | $186 | $6 |
| Automated urinalysis test | 53 | $162 | $2 |
2018: 13 services
| Return visit (30+ min) | 106 | $15,657 | $79 |
| New patient visit (45+ min) | 76 | $9,256 | $122 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 36 | $9,218 | $256 |
| Repair of herniated rectum into vaginal wall | 14 | $4,358 | $311 |
| Creation of sling around urethra in female to control leakage | 12 | $4,168 | $347 |
| Insertion of temporary bladder tube | 91 | $4,034 | $35 |
| New patient visit (60+ min) | 22 | $3,126 | $142 |
| Insertion of device into abdomen with pressure and urine flow rate study | 35 | $2,973 | $85 |
| Short return visit (20+ min) | 39 | $2,428 | $47 |
| Long return visit (40+ min) | 14 | $1,898 | $112 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 34 | $895 | $26 |
| Automated urinalysis test | 106 | $494 | $3 |
| Electronic assessment of bladder emptying | 35 | $211 | $6 |
2017: 13 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 18 | $4,442 | $247 |
| Creation of sling around urethra in female to control leakage | 12 | $4,428 | $369 |
| Return visit (30+ min) | 31 | $3,726 | $81 |
| Long return visit (40+ min) | 22 | $2,497 | $96 |
| New patient visit (60+ min) | 13 | $1,928 | $148 |
| Short return visit (20+ min) | 29 | $1,928 | $49 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $1,352 | $84 |
| Insertion of temporary bladder tube | 29 | $1,281 | $35 |
| Diagnostic exam of bladder and urethra using an endoscope | 14 | $1,140 | $81 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 14 | $369 | $26 |
| Automated urinalysis test | 47 | $287 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 15 | $248 | $14 |
| Electronic assessment of bladder emptying | 18 | $100 | $6 |
Drugs they prescribed that Part D paid
$172,053
Pharmacies billed $172,053 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (26 of 1,046) in 2024. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
747 generic and 299 brand-name prescriptions · $172,053 in drug cost · 211 antibiotic prescriptions to 78 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 135 | $76,878 | $569 |
| Gemtesa | 56 | $45,730 | $817 |
| Estradiol | 185 | $10,877 | $59 |
| Premarin | 12 | $3,636 | $303 |
| Tolterodine Tartrate Er | 46 | $3,065 | $67 |
See all 20 drugs
| Myrbetriq | 135 | $76,878 | $569 |
| Gemtesa | 56 | $45,730 | $817 |
| Estradiol | 185 | $10,877 | $59 |
| Premarin | 12 | $3,636 | $303 |
| Tolterodine Tartrate Er | 46 | $3,065 | $67 |
| Methenamine Hippurate | 51 | $3,030 | $59 |
| Trospium Chloride | 41 | $2,703 | $66 |
| Trimethoprim | 54 | $2,526 | $47 |
| Solifenacin | 52 | $1,346 | $26 |
| Nitrofurantoin Mono-Macro | 78 | $959 | $12 |
| Gabapentin | 36 | $791 | $22 |
| Nitrofurantoin | 12 | $418 | $35 |
| Cephalexin | 27 | $398 | $15 |
| Duloxetine | 12 | $282 | $24 |
| Oxybutynin Chloride Er | 17 | $173 | $10 |
| Sulfamethoxazole-Trimethoprim | 28 | $136 | $5 |
| Amitriptyline | 31 | $102 | $3 |
| Ibuprofen | 19 | $74 | $4 |
| Acetaminophen-Codeine | 14 | $50 | $4 |
| Fluconazole | 11 | $19 | $2 |
Year by year
| 2024 | 1,046 | 244 | 3% (26) | 29% | $172,053 |
| 2023 | 1,130 | 270 | 3% (29) | None | $222,355 |
| 2022 | 1,035 | 255 | 2% (22) | None | $180,273 |
| 2021 | 965 | 220 | 2% (17) | 38% | $183,161 |
| 2020 | 993 | 212 | None | 36% | $210,474 |
| 2019 | 944 | 180 | 1% (11) | 40% | $201,411 |
| 2018 | 803 | 153 | 3% (20) | 38% | $133,742 |
| 2017 | 295 | 76 | None | 32% | $36,696 |
| 2016 | 211 | 93 | 11% (23) | 36% | $26,398 |
| 2015 | 449 | 196 | 14% (62) | None | $45,029 |
| 2014 | 464 | 203 | 9% (42) | None | $49,659 |
| 2013 | 132 | 58 | 24% (31) | 13% | $5,702 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Myrbetriq | 195 | $123,141 | $631 |
| Gemtesa | 75 | $45,953 | $613 |
| Estradiol | 196 | $17,183 | $88 |
| Tolterodine Tartrate Er | 72 | $10,533 | $146 |
| Imvexxy | 11 | $4,872 | $443 |
| Methenamine Hippurate | 62 | $4,364 | $70 |
| Solifenacin | 80 | $3,089 | $39 |
| Trospium Chloride | 37 | $1,820 | $49 |
| Nitrofurantoin Mono-Macro | 110 | $1,533 | $14 |
| Trimethoprim | 28 | $815 | $29 |
| Nitrofurantoin | 16 | $658 | $41 |
| Oxybutynin Chloride Er | 22 | $460 | $21 |
| Amitriptyline | 25 | $174 | $7 |
| Acetaminophen-Codeine | 22 | $73 | $3 |
| Tamsulosin | 12 | $51 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $49 | $4 |
| Fluconazole | 14 | $39 | $3 |
2022: 19 drugs
| Myrbetriq | 183 | $106,483 | $582 |
| Estradiol | 167 | $17,855 | $107 |
| Tolterodine Tartrate Er | 79 | $13,373 | $169 |
| Premarin | 17 | $5,903 | $347 |
| Imvexxy | 14 | $5,731 | $409 |
| Methenamine Hippurate | 65 | $5,703 | $88 |
| Solifenacin | 51 | $3,199 | $63 |
| Trimethoprim | 37 | $1,588 | $43 |
| Nitrofurantoin Mono-Macro | 88 | $1,479 | $17 |
| Trospium Chloride Er | 12 | $1,138 | $95 |
| Trospium Chloride | 21 | $1,054 | $50 |
| Oxybutynin Chloride Er | 16 | $603 | $38 |
| Clotrimazole-Betamethasone | 13 | $522 | $40 |
| Tamsulosin | 44 | $203 | $5 |
| Amitriptyline | 16 | $179 | $11 |
| Fluconazole | 26 | $100 | $4 |
| Acetaminophen-Codeine | 19 | $82 | $4 |
| Sulfamethoxazole-Trimethoprim | 27 | $68 | $3 |
| Cephalexin | 11 | $38 | $3 |
2021: 17 drugs
| Myrbetriq | 174 | $93,266 | $536 |
| Estradiol | 182 | $19,687 | $108 |
| Toviaz | 30 | $16,602 | $553 |
| Tolterodine Tartrate Er | 98 | $15,566 | $159 |
| Premarin | 27 | $8,207 | $304 |
| Estring | 12 | $5,863 | $489 |
| Solifenacin | 42 | $3,114 | $74 |
| Methenamine Hippurate | 25 | $2,225 | $89 |
| Trospium Chloride Er | 11 | $1,732 | $157 |
| Trospium Chloride | 18 | $1,184 | $66 |
| Clobetasol Propionate | 22 | $1,137 | $52 |
| Nitrofurantoin Mono-Macro | 54 | $1,010 | $19 |
| Oxybutynin Chloride Er | 15 | $524 | $35 |
| Trimethoprim | 26 | $220 | $8 |
| Clotrimazole-Betamethasone | 16 | $201 | $13 |
| Imipramine | 21 | $98 | $5 |
| Sulfamethoxazole-Trimethoprim | 34 | $72 | $2 |
2020: 19 drugs
| Myrbetriq | 192 | $105,028 | $547 |
| Estradiol | 156 | $24,846 | $159 |
| Toviaz | 46 | $18,130 | $394 |
| Tolterodine Tartrate Er | 56 | $9,540 | $170 |
| Premarin | 20 | $8,050 | $402 |
| Estring | 17 | $7,867 | $463 |
| Solifenacin | 75 | $6,596 | $88 |
| Vesicare | 12 | $5,621 | $468 |
| Methenamine Hippurate | 34 | $3,024 | $89 |
| Trospium Chloride | 29 | $2,749 | $95 |
| Nitrofurantoin Mono-Macro | 51 | $904 | $18 |
| Cimetidine | 11 | $750 | $68 |
| Oxybutynin Chloride Er | 17 | $568 | $33 |
| Clotrimazole-Betamethasone | 31 | $421 | $14 |
| Imipramine | 28 | $150 | $5 |
| Fluconazole | 20 | $127 | $6 |
| Trimethoprim | 20 | $101 | $5 |
| Sulfamethoxazole-Trimethoprim | 28 | $76 | $3 |
| Ciprofloxacin | 14 | $42 | $3 |
2019: 20 drugs
| Myrbetriq | 170 | $83,597 | $492 |
| Estradiol | 137 | $27,402 | $200 |
| Vesicare | 40 | $20,423 | $511 |
| Toviaz | 38 | $15,536 | $409 |
| Tolterodine Tartrate Er | 71 | $11,424 | $161 |
| Premarin | 35 | $10,739 | $307 |
| Estring | 14 | $6,083 | $435 |
| Estrace | 17 | $5,845 | $344 |
| Solifenacin | 27 | $3,927 | $145 |
| Trospium Chloride | 50 | $3,145 | $63 |
| Methenamine Hippurate | 32 | $2,974 | $93 |
| Nitrofurantoin Mono-Macro | 47 | $862 | $18 |
| Cimetidine | 12 | $748 | $62 |
| Clotrimazole-Betamethasone | 18 | $343 | $19 |
| Amitriptyline | 17 | $330 | $19 |
| Sulfamethoxazole-Trimethoprim | 38 | $113 | $3 |
| Trimethoprim | 12 | $81 | $7 |
| Imipramine | 12 | $64 | $5 |
| Fluconazole | 15 | $62 | $4 |
| Ciprofloxacin | 15 | $57 | $4 |
2018: 18 drugs
| Myrbetriq | 94 | $40,369 | $429 |
| Estradiol | 100 | $22,525 | $225 |
| Vesicare | 47 | $17,428 | $371 |
| Toviaz | 25 | $7,922 | $317 |
| Estrace | 25 | $7,913 | $317 |
| Estring | 17 | $7,183 | $423 |
| Premarin | 20 | $7,024 | $351 |
| Methenamine Hippurate | 62 | $4,953 | $80 |
| Tolterodine Tartrate Er | 29 | $4,413 | $152 |
| Trospium Chloride | 54 | $3,890 | $72 |
| Yuvafem | 17 | $3,221 | $189 |
| Nitrofurantoin Mono-Macro | 52 | $1,598 | $31 |
| Amitriptyline | 17 | $310 | $18 |
| Sulfamethoxazole-Trimethoprim | 58 | $274 | $5 |
| Fluconazole | 12 | $70 | $6 |
| Metronidazole | 11 | $67 | $6 |
| Acetaminophen-Codeine | 11 | $56 | $5 |
| Ibuprofen | 11 | $48 | $4 |
2017: 9 drugs
| Estrace | 37 | $10,497 | $284 |
| Premarin | 23 | $7,882 | $343 |
| Myrbetriq | 21 | $6,886 | $328 |
| Vesicare | 11 | $3,932 | $357 |
| Methenamine Hippurate | 19 | $1,651 | $87 |
| Trospium Chloride | 16 | $684 | $43 |
| Nitrofurantoin Mono-Macro | 21 | $481 | $23 |
| Sulfamethoxazole-Trimethoprim | 30 | $116 | $4 |
| Ciprofloxacin | 17 | $71 | $4 |
2016: 7 drugs
| Myrbetriq | 27 | $8,517 | $315 |
| Premarin | 22 | $6,473 | $294 |
| Estrace | 13 | $3,388 | $261 |
| Nitrofurantoin | 13 | $275 | $21 |
| Polyethylene Glycol 3350 | 12 | $204 | $17 |
| Oxycodone-Acetaminophen | 15 | $155 | $10 |
| Ibuprofen | 17 | $76 | $4 |
2015: 13 drugs
| Premarin | 58 | $14,666 | $253 |
| Estrace | 35 | $8,778 | $251 |
| Vesicare | 27 | $8,216 | $304 |
| Oxybutynin Chloride Er | 11 | $1,087 | $99 |
| Polyethylene Glycol 3350 | 41 | $708 | $17 |
| Oxycodone-Acetaminophen | 47 | $541 | $12 |
| Nitrofurantoin | 27 | $500 | $19 |
| Nitrofurantoin Mono-Macro | 14 | $430 | $31 |
| Baclofen | 12 | $238 | $20 |
| Ibuprofen | 50 | $222 | $4 |
| Lidocaine | 16 | $197 | $12 |
| Sulfamethoxazole-Trimethoprim | 17 | $63 | $4 |
| Ciprofloxacin | 14 | $48 | $3 |
2014: 16 drugs
| Premarin | 78 | $16,857 | $216 |
| Myrbetriq | 14 | $6,807 | $486 |
| Estrace | 39 | $6,578 | $169 |
| Vesicare | 23 | $5,068 | $220 |
| Toviaz | 13 | $4,303 | $331 |
| Baclofen | 25 | $483 | $19 |
| Nitrofurantoin Mono-Macro | 14 | $474 | $34 |
| Nitrofurantoin | 18 | $374 | $21 |
| Clotrimazole-Betamethasone | 11 | $309 | $28 |
| Oxycodone-Acetaminophen | 27 | $252 | $9 |
| Polyethylene Glycol 3350 | 12 | $251 | $21 |
| Lidocaine | 12 | $198 | $17 |
| Imipramine | 19 | $170 | $9 |
| Lactulose | 13 | $112 | $9 |
| Ciprofloxacin | 28 | $111 | $4 |
| Ibuprofen | 29 | $111 | $4 |
2013: 5 drugs
| Premarin | 11 | $2,263 | $206 |
| Polyethylene Glycol 3350 | 16 | $450 | $28 |
| Nitrofurantoin | 11 | $214 | $19 |
| Ibuprofen | 29 | $111 | $4 |
| Oxycodone-Acetaminophen | 20 | $109 | $5 |
Money from drug and device companies
$998 in 2025
| 2025 | 3 | 12 | None | $998 |
| 2024 | 3 | 7 | None | $600 |
| 2023 | 5 | 12 | None | $850 |
| 2022 | 8 | 10 | None | $869 |
| 2021 | 4 | 6 | None | $273 |
| 2020 | 2 | 2 | None | $80 |
| 2019 | 5 | 12 | $300 | $1,625 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Altaviva | $815 | 8 payments
|
| Coloplast | Supris | $163 | 3 payments
|
| Bluewind Medical | Revi | $19 | 1 payment
|
See all 12 published payments
| Medtronic | Travel · 2025-11-30 | Altaviva | $7 |
| Medtronic | Travel · 2025-11-09 | Altaviva | $25 |
| Medtronic | Travel · 2025-11-08 | Altaviva | $169 |
| Medtronic | Travel · 2025-11-08 | Altaviva | $19 |
| Medtronic | Meals · 2025-11-07 | Altaviva | $28 |
| Medtronic | Meals · 2025-11-07 | Altaviva | $40 |
| Medtronic | Travel · 2025-10-28 | Altaviva | $491 |
| Medtronic | Travel · 2025-10-28 | Altaviva | $35 |
| Bluewind Medical | Meals · 2025-10-24 | Revi | $19 |
| Coloplast | Meals · 2025-10-16 | Supris | $17 |
| Coloplast | Meals · 2025-10-16 | Supris | $132 |
| Coloplast | Meals · 2025-10-16 | Altis | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $600
| Medtronic | Interstim | $320 | 3 payments
|
| Boston Scientific | Solyx Sis System | $186 | 3 payments
|
| Coloplast | Altis | $94 | 1 payment
|
2023: $850
| Medtronic | Interstim | $552 | 8 payments
|
| Boston Scientific | Solyx Sis System | $118 | 1 payment
|
| Axonics | Axonics | $117 | 1 payment
|
| Coloplast | Saffron | $34 | 1 payment
|
| Applied Medical Resources | None | $29 | 1 payment
|
2022: $869
| Medtronic | Interstim | $203 | 2 payments
|
| Axonics | Bulkamid | $187 | 2 payments
|
| Coloplast | Altis | $169 | 1 payment
|
| Genentech USA | None | $124 | 1 payment
|
| Astellas Pharma US | None | $100 | 1 payment
|
| Boston Scientific | General - Female Sui | $39 | 1 payment
|
| Bolder Surgical | Coolseal Generator | $34 | 1 payment
|
| TherapeuticsMD | Annovera | $13 | 1 payment
|
2021: $273
| Boston Scientific | Solyx | $168 | 3 payments
|
| Astellas Pharma US | None | $52 | 1 payment
|
| Medtronic | Interstim | $38 | 1 payment
|
| Caldera Medical | Desara | $16 | 1 payment
|
2020: $80
| Boston Scientific | Advantage Fit | $52 | 1 payment
|
| Medtronic USA | Interstim | $28 | 1 payment
|
2019: $1,625
| Coloplast | Altis | $641 | 7 payments
|
| Boston Scientific | General Pelvic Organ Prolapse | $356 | 1 payment
|
| BioFire Diagnostics | Biofire Filmarray | $300 | 1 payment
|
| Medtronic USA | Interstim | $250 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $79 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Medtronic, Inc. · 2024 | This clinician | $551 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003047515
- Licence
- CA DEA0009752, TX Q9107Texas Q9107: Canc Non-Renewal
- Trained
- University of Texas Medical Branch at Galveston, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 361926401
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 207VF0040X (207VF0040X)
- Mailing address
- 4725 1st St Ste 100, Pleasanton, CA, 94566
- NPI first listed
- 2009-07-31
- NPI last updated
- 2024-11-05
- NPI record certified
- 2024-11-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 8300 Floyd Curl Dr Fl 5, San Antonio, TX, 78229